Aldeyra Therapeutics, Inc.
ALDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $229,974 | $344,350 | $296,830 |
| - Cash | $59,341 | $41,241 | $50,351 | $54,527 |
| + Debt | $73 | $15,556 | $15,567 | $15,303 |
| Enterprise Value | – | $204,289 | $309,566 | $257,606 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | -$64 |
| % Margin | – | – | – | – |
| EBITDA | -$7,149 | -$9,234 | -$9,385 | -$15,274 |
| % Margin | – | – | – | – |
| Net Income | -$7,688 | -$9,767 | -$9,930 | -$15,809 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.13 | -0.16 | -0.17 | -0.27 |
| % Growth | 18.8% | 5.9% | 37% | – |
| Operating Cash Flow | -$7,021 | -$8,555 | -$12,470 | -$12,037 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$7,021 | -$8,555 | -$12,470 | -$12,037 |